Manganese based MR contrast agents: Formulation and clinical applications

Open Drug Safety Journal

Volumn 2, Issue 1, 2011, Pages 29-38

  Chabanova, Elizaveta ^a   Logager, Vibeke B ^a   Moller, Jakob M ^a   Thomsen, Henrik S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biliary tree; cancer; chemotherapy; cirrhosis; CMC 001; gallbladder; liver; Mangafodipir; Manganese; metabolism; metastases; pancreas; positive contrast agent

Indexed keywords

ALANINE; CMC 001; COLECALCIFEROL; FLUORODEOXYGLUCOSE; MANGAFODIPIR; MANGANESE CHLORIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIARY EXCRETION; BONE MALFORMATION; CARDIOTOXICITY; CHEMICAL COMPOSITION; COLD SENSATION; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; FLUSHING; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INJECTION SITE PAIN; INJECTION SITE WARMTH; INTERMETHOD COMPARISON; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MITOCHONDRION; MORTALITY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TERATOGENICITY; VOMITING;

EID: 82855179425     PISSN: None     EISSN: 18768180     Source Type: Journal    
DOI: 10.2174/1876818001102010029     Document Type: Article

References (46)

1. Santamaria AB, Sulsky SI. Risk assessment of an essential element: manganese. J Toxicol Environ Health A 2010; 73: 128-55.
2. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium and manganese-based T1 contrast agents. Contrast Media Mol Imaging 2009; 4: 89-100.
3. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin Noth Am 2005; 43: 887-98.
4. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of liver: properties, clinical development and applications. Eur Radiol 2004; 14: 559-78.
5. Martin DR, Semelka RC. Magnetic resonance imaging of the liver: review of techniques and approach to common diseases. Semin Ultrasound CT MR 2005; 26: 116-31.
6. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin Noth Am 2005; 43: 887-98.
7. Chabanova E, Thomsen HS, Logager V, et al. Effect of new manganese contrast agent on tissue intensities: comparison of 0.23 T, 0.6T and 1.5 T MRI. A part of a phase I trial. MAGMA 2004; 17: 28-35.
8. Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes H. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 1997; 38: 631-7.
9. Thomsen HS, Loegager V, Noergaard H, Chabanova E, Moller JM, Sonne J. Oral manganese for liver imaging at three different field strengths. Acad Radiol 2004; 11: 630-6.
10. Bellin M-F, Webb JAW, Van Der Molen AJ, Thomsen HS, Morcos SK. Safety of MR liver specific contrast media. Eur Radiol 2005; 15: 1607-16.
11. Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med 1996; 35: 14-9.
12. Hustvedt SO, Grant D, Southon TE, Zech K. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after IV administration. Acta Radiol 1997; 38: 690-9.
13. Federle MP, Chezmar JL, Rubin DL, et al. Safety and efficacy of Mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety). J Magn Reson Imaging 2000; 12: 186-97.
14. Elizondo G, Fretz CJ, Stark DD. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991; 178: 73-8.
15. Thomsen HS, Svendsen O, Klastrup S. Increased manganese concentration in the liver after oral intake. Acad Radiol 2004; 11: 38-44.
16. Chabanova E, Logager V, Moller JM, Dekker H, Barentsz J, Thomsen HS. Imaging liver metastases with a new oral manganese based contrast agent. Acad Radiol 2006; 13: 827-32.
17. Thomsen HS, Barentsz JO, Burcharth F, et al. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. Eur Radiol 2007; 17: 273-8.
18. Kim HJ, Kim KW, Byun JH, et al. Comparison of mangafodipir trisodiumand ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. Am J Roentgenol 2006; 186: 1059-66.
19. Kanematsu M, Kondo H, Goshima S, et al. Imaging liver metastases: review and update. Eur J Radiol 2006; 58: 217-28.
20. Toft KG, Hustvedt SO, Grant D, et al. Metabolism and pharmacokinetics of MnDPDP in man. Acta Radiol 1997; 38: 677-89.
21. Underwood EJ. Manganese. In: Underwood EJ, Ed. Trace elements in human and animal nutrition. New York, NY Academic Press 1971; pp. 177-207.
22. Mena I. Manganese. In: Bronner F, Coburn JW, Ed. Disorders on mineral metabolism. New York, NY Academic Press 1981; pp. 233-70.
23. Cooper WC. The health complications of increased manganese in the environment resulting from combustion of fuel additives: a review of the literature. J Toxicol Environ Health 1984; 14: 23-46.
24. Mirowitz SA, Westrich TJ, Hinsch JD. Hypertensive basal ganglia on T1-weighed MR images in patients receiving parenteral nutrition. Radiology 1991; 181: 117-20.
25. Rummeny E, Ehrenheim C, Gehl HB, et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 1991; 26(Suppl 1): S142-5; discussion S150-5.
26. Aicher KP, Laniado M, Kopp AF, Gronewaller E, Duda SH, Claussen CD. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients. J Magn Reson Imaging 1993; 3: 731-7.
27. Wang C, Ahlstrom H, Ekholm S, et al. Diagnostic efficacy of Mn DPDP in MR imaging of the liver. A phase III multicenter study. Acta Radiol 1997; 38: 643-9.
28. Wolf GL, Baum SL. Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. Am J Roentgenol 1983; 141: 193-7.
29. Conrad LL, Trendly RL, Baxter DJ. Positive inotropic effect of manganese in dog myocardium. Am J Physiol 1966; 210: 357-9.
30. Brurok H, Schøojtt J, Berg K, Karlsson JOG, Jynge P. Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphateand manganese chloride on cardiac function: An experimental study in the langendorff perfused rat heart. Invest Radiol 1955; 30: 159-67.
31. Kojima S, Hirai M, Kiyozumi M, Sasawa Y, Nakagawa M, Shin-O T. Studies of poisonous metals. X metabolic fate og manganese after oral administration of excessive manganese chloride in rats. Chem Pharm Bull 1983; 31: 2459-65.
32. Mahoney JP, Small WJ. Studies of manganese: III. The biological half-life of radiomanganese in man factors which affect this lifetime. J Clin Invest 1968; 47: 643-53.
33. Kreft BP, Baba Y, Tanimoto A, Finn JP, Stark DD. Orally administered manganese chloride: Enhanced detection of hepatic tumours in rats. Radiology 1993; 186: 543-8.
34. Jynge P, Brurok H, Asplund A, Towart R, Refsum H, Karlsson JO. Cardiovascular safety of MnDPDP and MnCl2. Acta Radiol 1997; 38: 740-9.
35. Grant D, Blazak WF, Brown GL. The reproductive toxicology of intravenously administered MnDPDP in the rat and rabbit. Acta Radiol 1997; 38: 759-69.
36. Blazak WF, Brown GL, Gray TJ, Treinen KA, Denny KH. Developmental toxicity study of Mangafodipir trisodium injection (MnDPDP) in New Zealand white rabbits. Fundam Appl Toxicol 1996; 33: 11-5.
37. Misselwitz B, Muhler A, Weinmann HJ. A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Ivest Radiol 1995; 30: 611-20.
38. Larsen E, Grant D. General toxicology of MnDPDP. Acta Radiol 1997; 38: 770-9.
39. Southon TE, Grant D, Bjornerud A, et al. NMR relaxation studies with MnDPDP. Acta Radiol 1997; 38: 708-16.
40. Bartolozzi C, Donati F, Cioni D, et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 2004; 14: 14-20.
41. Regge D, Campanella D, Anselmetti GC, et al. Diagnostic accuracy of portal-phase CT and MRI with Mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. Clin Radiol 2006; 61: 338-47.
42. Kim KW, Kim AY, Kim TK, et al. Small (
43. Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of Mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. Am J Roentgenol 2005; 185: 239-46.
44. Marti-Bonmati L, Fog AF, de Beeck BO, Kane P, Fagertun H. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 2003; 13: 1685-92.
45. Fayad LM, Kamel IR, Mitchell DG, Bluemke DA. Functional MR cholangiography: Diagnosis of functional abnormalities of the gallbladder and biliary tree. Am J Roentgenol 2005; 184: 1563-71.
46. Boraschi P, Donati F, Gigoni R, et al. Mangafodipir trisodium enhanced MR imaging of pancreatic disease. Eur Radiol 2006; 16: 988-97.